Skip to main content
SpringerLink
Log in

Amiodarone-treated patients with suppressed TSH test are at risk of thyrotoxicosis

  • Originalien
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

Therapeutic use of the potent antiarrhythmic drug amiodarone requires early detection of impending hyperthyroidism, a potentially life-threatening adverse reaction in cardiac patients. Since amiodarone inhibits peripheral conversion of thyroxine (T4) to triiodothyronine (T3), serum T4 and T3 levels become unreliable parameters of thyroid function. In 44 patients treated with amiodarone for a median period of 7.3 months, up to seven TRH-TSH tests were performed. The TSH response to TRH was normal in 23 patients, partially suppressed in eight, totally suppressed in eight and overshooting in five patients. Two of the eight patients with suppressed TRH-TSH tests were clinically hyperthyroid, in four others thyrotoxicosis developed within 1 to 2 1/2 months after the first observation of a suppressed TSH response, while two patients remained euthyroid. In all patients with negative TRH-TSH tests, TSH response to TRH returned to normal between 2 and 29 months after withdrawal of amiodarone. We conclude that the TRH-TSH test, repeated at intervals, is a reliable tool for assessing thyroid function in patients on long-term treatment with amiodarone. Patients with a suppressed response under amiodarone therapy are at risk of developing thyrotoxicosis. Normalization of the TSH response indicates that this risk is over.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

T3:

triiodothyronine

T4:

thyroxine

TRH:

thyrotropine-releasing hormone

TSH:

thyroid-stimulating hormone

RIA:

radioimmunoassay

References

  1. Bauthier J, Broekhuysen J, Charlier R, Richard J (1976) Nature of the inhibition by amiodarone of isoproterenol-induced tachycardia in the dog. Arch Int Pharmacodyn 219:45–51

    Google Scholar 

  2. Burger A, Dinichert D, Nicod P, Jenny M, Lemarchand-Béraud T, Vallotton MB (1976) Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin and thyrotropin. J Clin Invest 28:255–259

    Google Scholar 

  3. Debbas NMG, Du Cailar C, Sassine A, Derancourt J, Demaille JG, Puech P (1983) Determination of cardiac and plasma drug levels during long-term amiodarone therapy. Eur J Clin Invest 13:123–127

    Google Scholar 

  4. Fradkin JE, Wolff J (1982) Iodide-induced thyrotoxicosis. Medicine 62:1–20

    Google Scholar 

  5. Gemsenjäger E, Staub JJ, Girard J, Heitz Ph (1976) Preclinical hyperthyroidism in multinodular goiter. J Clin Endocrinol Metab 43:810–816

    Google Scholar 

  6. Goedel-Meinen L, Schmidt G, Wirtzfeld A, Jahns G, Klein G, Böttger I, Ulm K, Baedeker W (1984) Einfluß von Amiodarone auf die Schilddrüsenfunktion. Z Kardiol 73:399–404

    Google Scholar 

  7. Goldfine ID, Maddux B, Woeber KA (1982) Effect of amiodarone on L-triiodothyronine stimulation of 3H-thymidine incorporation into GH3 cells. J Endocrinol Invest 5:165–168

    Google Scholar 

  8. Harris L, McKenna WJ, Rowland E, Holt DW, Storey GCA, Krikler DM (1983) Side effects of long-term amiodarone therapy. Circulation 67:45–51

    Google Scholar 

  9. Heger JJ, Prystowsky EN, Jackman WM, Naccarelli GV, Warfel KA, Rinkenberger RL, Zipes DP (1981) Amiodarone. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med 305:539–545

    Google Scholar 

  10. Holt D, Tucker GT, Jackson PR, Storey GCA (1983) Amiodarone pharmacokinetics. Am Heart J 106:840–847

    Google Scholar 

  11. Jaggarao NSV, Sheldon J, Grundy EN, Vincent R, Chamberlain DA (1982) The effects of amiodarone on thyroid function. Postgrad Med J 58:693–696

    Google Scholar 

  12. Jonckheer MH (1981) Amiodarone and the thyroid gland. A review. Acta Cardiol (Brux) 36:199–205

    Google Scholar 

  13. Jonckheer MH, Blockx P, Broeckaert I, Cornette C, Beckers C (1978) “Low T3 syndrome” in patients chronically treated with an iodine-containing drug, amiodarone. Clin Endocrinol 9:27–35

    Google Scholar 

  14. Kannan R, Nademanee K, Hendrickson JA, Rostami HJ, Singh BN (1982) Amiodarone kinetics after oral doses. Clin Pharmacol Ther 31:438–444

    Google Scholar 

  15. Lambert MJ, Burger AG, Galeazzi RL, Engler D (1982) Are selective increases in serum thyroxine (T4) due to iodinated inhibitors of T4 monodeiodination indicative of hyperthyroidism? J Clin Endocrinol Metab 55:1058–1065

    Google Scholar 

  16. Lauber K (1975) Iodine determination in biological material. Kinetic measurement of the catalytic activity of iodine. Anal Chem 47:769–771

    Google Scholar 

  17. Martino E, Safran M, Aghini-Lombardi F, Rajatanavin R, Lenziardi M, Fay M, Pacchiarotti A, Aronin N, Macchia E, Haffajee Ch, Odoguardi L, Love J, Bigalli A, Baschieri L, Pinchera A, Braverman L (1984) Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 101:28–34

    Google Scholar 

  18. McComb JM, Logan KR, Khan MM, Geddes JS, Adgey AAJ (1980) Amiodarone-induced ventricular fibrillation. Eur J Cardiol 11:381–385

    Google Scholar 

  19. Melmed S, Nademanee K, Reed AW, Hendrickson JA, Singh BN, Hershman JM (1981) Hyperthyroxinemia with bradycardia and normal thyrotropin secretion after chronic amiodarone administration. J Clin Endocrinol Metab 53:997–1001

    Google Scholar 

  20. Nademanee K, Hendrickson JA, Cannom DS, Goldreyer BN, Singh BN (1981) Control of refractory life-threatening ventricular tachyarrhythmias by amiodarone. Am Heart J 101:759–768

    Google Scholar 

  21. Nademanee K, Singh BN, Hendrickson JA, Reed AW, Melmed S, Hershman J (1982) Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. Circulation 66:202–211

    Google Scholar 

  22. Pickardt CR, Theisen F, Witte A, Leisner B, Theisen K, Jahrmärker H (1983) Effects of long-term treatment with amiodarone on thyroid function and thyroidal iodine concentration. In: Breithardt G, Loogen F (eds) New aspects in the medical treatment of tachyarrhythmias. Urban & Schwarzenberg, München, p 245–248

    Google Scholar 

  23. Platzer R, Wimpfheimer C, Bürgi H (1982) Use of a single TSH-measurement after oral thyrotropin-releasing hormone: an economical and highly sensitive screening test. Acta Endocrinol 10:369–372

    Google Scholar 

  24. Podrid PJ, Lown B (1981) Amiodarone therapy in symptomatic, sustained refractory atrial and ventricular tachyarrhythmias. Am Heart J 101:374–379

    Google Scholar 

  25. Rosenbaum MB, Chiale PA, Halpern MS, Nau J, Przybylski J, Levi RJ, Lazzari JO, Elizari MV (1976) Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol 38:934–944

    Google Scholar 

  26. Sachs L (1974) Angewandte Statistik: Planung und Auswertung, Methoden und Modelle. Fourth Edition. Springer, Berlin Heidelberg

    Google Scholar 

  27. Savoie JC, Massin JP, Thomopoulos P, Leger F (1975) Iodine-induced thyrotoxicosis in apparently normal thyroid glands, J Clin Endocrinol 41:685–691

    Google Scholar 

  28. Singh BN, Nademanee K (1983) Amiodarone and thyroid function: Clinical implications during antiarrhythmic therapy. Am Heart J 106:857–868

    Google Scholar 

  29. Singh BN, Vaughan Williams EM (1970) The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol 39:657–667

    Google Scholar 

  30. Sobol SM, Rakita L (1982) Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug. Circulation 65:819–824

    Google Scholar 

  31. Stäubli M, Bircher J, Galeazzi RL, Remund H, Studer H (1983) Serum concentrations of amiodarone during long-term therapy. Relation to dose, efficacy, toxicity. Eur J Clin Pharmacol 24:485–494

    Google Scholar 

  32. Stäubli M, Bischof P, Wimpfheimer C, Studer H (1981) Amiodaron (Cordarone) und Schilddrüse. Schweiz Med Wochenschr 111:1590–1596

    Google Scholar 

  33. Tartini R, Kappenberger L, Steinbrunn W, Meyer UA (1982) Dangerous interaction between amiodarone and quinidine. Lancet 1:1327–1329

    Google Scholar 

  34. Wellens HJJ, Lie KI, Bär FW, Wesdorp JC, Dohmen HJ, Düren DR, Durrer D (1976) Effect of amiodarone in the Wolff-Parkinson-White syndrome. Am J Cardiol 38:189–194

    Google Scholar 

  35. Wemeau JL, Decoulx M, Grimbert I, Ducloux G, Linquette M (1982) Amiodarone et fonction thyroïdienne. Therapie 37:95–102

    Google Scholar 

  36. Wimpfheimer C, Stäubli M, Schädelin J, Studer H (1982) Prednisone in amiodarone-induced thyrotoxicosis. Br Med J 284:1835–1836

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Universitätsklinik, Inselspital Bern, Schweiz

    M. Stäubli & H. Studer

Authors
  1. M. Stäubli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Studer
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This work was supported by the Swiss National Science Foundation, Grant no. 3.848-0.81

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stäubli, M., Studer, H. Amiodarone-treated patients with suppressed TSH test are at risk of thyrotoxicosis. Klin Wochenschr 63, 168–175 (1985). https://doi.org/10.1007/BF01732171

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01732171

Key words

Search

Navigation